• Elicio Therapeutics posted a net loss of $11.8 million, or $0.65 per share, for the quarter ended March 31, 2026, versus a net loss of $11.2 million, or $0.87 per share, a year earlier.
• R&D expense fell 13.1% to $6.8 million, while G&A expense climbed 28.4% to $3.8 million.
• Cash and cash equivalents totaled $14.9 million at quarter-end, down from $18.6 million at Dec. 31, 2025.
• Net proceeds raised through the at-the-market program reached about $13 million, including $8 million in Q1 and an additional $5 million in Q2 to date.
• Event-driven primary disease-free survival analysis from Phase 2 AMPLIFY-7P trial of ELI-002 7P in post-resection mKRAS pancreatic cancer remains expected mid-year 2026, with cash runway projected into Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605111605PRIMZONEFULLFEED9717695) on May 11, 2026, and is solely responsible for the information contained therein.